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ABSTRACT
Previous research has shown ttrat androstenedione supplementation does not increase
testosterone levels in young to middle age men. It has been speculated that the
supplement doesnot alter testosterone in these men because their testosterone levels were
normal prior to participating in the respective studies. Androstenedione may only
increase testosterone in individuals who have a low testosterone level. The primary
purposes ofthis study, therefore, was to determine if androstenedione supplementation
alters testosterone in older merL who have lower natural testosterone levels than younger
counterparts. A secondary purpose was to detennine if the supplement altered moo4
perceived exertion" or testosterone levels with exercise. Twenty-five males, 55 to 85
years of age, served as subjects. Each had been exercising consistently for a minimum of
3 months and had a relatively stable health background (no cardiac events within the past
5 years). Subjects were randomly assigned to either the heatnent or control group,
which consumed 200 mg of androstenedione or placebo, respectively. Immediately after
fieatnent, subjects completed a short form of the Profile of Mood Questionnaire (POMS)
and provided a salvia sample, which was subsequently ane.lyzrd for testosterone
concentration. Subjects then completed a prescribed 30 min workout that included
resistance and cardiovascular exercise. lmmediately after completing each exercise,
subjects rated their perceived exertion (RPE) with the Borg scale. Additional salvia
samples were taken at 60 and 120 min post-treaftnent, whereas mood was reassessed
immediately following exercise and 180 min post treatment. A 2 x 3 (group x time)
analysis of variance (ANOVA) with repeated measures on the second factor was used to
examine differences in testosterone levels and mood over time and betrreen groups. A
composite RPE score for all exercises performed was calctrlated. A rwo-sample t-test was
used to asisess between goup differences in perceived exertion Androstenedione
supplementation did not alter testosterone levels acnoss time or benveen groups. There
were also no differences between the grorrps in the variables measured by the POMS,
which included anger, vigor, and fatigue. Relative to baseline, however, fatigue
increased during exercise and decreased after exercise in both groups, whereas anger
decreased both during exercise and after in both grcups regardless of treatmenl There
was also no difference in RPE between the groups. Single dose androstenedione
supplementation did not affect testosterone levels in older males even though they had
below normal initial testosterone levels. These results suggest that a ceiling effect of
naturally occurring testosterone does not appear to explain the lack of conversion of
orally consumed androstenedione to testosterone. In additioq since there were no
differences between the groups in RPE or POMS, the supplement also does not alter
perception or mood during exercise. Collectively, these data show that older males will
not benefit from androstenedione supplementation.
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ChaPter I
INTRODUCTION
Androgens are hormones secreted by the testes and adrenal glands that stimutate
the formation of secondary male sexual characteristics zuch as: auxiliary hair growth
(both facial and body), deepening ofthe voice, bone and muscle developme'lr! acne, and
mattuing of sexual organs (Flieger, 1995). The most predominant androgen is
testosterone. Testosterone levels are elevated prior to birth, then drop substantially
afterwards. A sharp rise is seen at pubrty, with peak levels reached in the twenties
(Greenspan & Baxter, lgg4). There is a gradual decline in testosterone production
throughout the rernainder of the lifespan. This progressive testosterone decline is linked
to andropause, which is characterized by a decline in intellectual acumen and sexual
functioning, along with an increase in affiominal obesity and muscle ahophy (Smith,
lgg4). These syrrptoms are similar to those of hypogonadism, wtrich affects an
estimated four to five million men in America (Rodgers, I995).
Numerous treatments have been developed to rectiff andropause and
hypogonadism. One such purported treafinent is androstenedione, a natural precursor to
testosterone, which is converted to testosterone within the human testes by the enzfme
l7p-hydroxysteroid dehydrogenase (King et al., 1999). Sold over-the-counter as a
dietary supplemen! androstenedione is administered through a nasal sPBY, subcutaneous
patc[ or as a pill, which is the most commonly used method due to its low cost and
convenience. If androstenedione supplementation can elevate testosterone levels, then
the effects of male menopause would be reduced, as sexual firnctioning, energy levels,
psychological well-being, bone density, and lean body mass should improve (Sadovsky,
2lgg7). ln shor! alrdrostenedione supplementation may be a forrr of androgen
replacement therapy (ART) for men simitsl to the estrogen therapy that women have
been prescribed since the 1940's (Coney, 1994)-
To bc an effective therapeutic modality, androstenedione supplementation must
increase tes0osterone levels. Recent research has showru however, that oral consumption
of androstenedione by yorrng and middle age men has little to no effect on testosterone
levels (King et al., |$9;Rasmussen, Volpi, Gore, & Wolfe, 2000; Wallace, Linr' Cufler,
& Bucci, 1999). Instead of elevating testosterone in this zubject cohort androstenedione
supplementation elevated estrogen levels. Apparently androstenedione bypassed the
more common testosterone pathway and was instead converted into estrone, a strong
estrogen.
Since the young subjects in the aforeme,ntioned studies had normal testosterone
levels, which are O?icatly gre,ater than in males from 55 to 80 years, it is possible that the
ingested supplement was not be converted to testosterone (Simon, Nahoul, & Chades'
1996;Venneulen, 1996). The authors offered that a ceiling had been reached. Such an
event explains the increase in estrogen. Since the androstenedione could not be converted
to testosterone, the only way to eliminate it was via the less common estrogen pathway.
Malresh & Greenblatt(1962) provided additional indirect evidence for the ceiling effect
hypothesis, as they showed that androstenedione increased testosterone levels in women.
Since women have lower testosterone levels than men, the androstenedione supplement
elevated testosterone in the females rather than being converted to estrogen.
The primary purpose of this study was to test the ceiling hypothesis by
determining if androstenedione supplementation increases testosterone levels in older
3males, who typically have lower testosterone levels tlran those tested in previous studies-
The testosterone levels of the subjects usod in this study ttpically range from 37G617
ng.dl-I. Subjects in the aforementioned snrdies, who were 35 and younger, had an average
testosterone level between 6l7468ng.dl-1. Since inadequate testosterone levels lower
energy and depress mood stateq they can theoretically decrease exercise perforrrance
(FDA Consumer, 1996). A secondary purpose of this study was to determine if the
supplernent altered moo4 perceived exertion, or testosterone levels with exercise-
Statement of the Problem
To study effects of androstenedione supplernantation on testosterone levels and
mood state in older men before and after exercise'
Major and Minor Hlpotheses
The major null hypothesis for this study was:
l. Androstenedione wilt have no effect on testosterone levels before or after
exercise.
The minor hypothesis for this investigation was:
l. Androstenedione will have no effect on mood state before or after exercise.
Z. Androstenedione will have no effect on perception of exertion during exercise
performance.
Assumptions of the Study
For the purpose of this study, the following assumptions were made when
ptanning the investi gation:
1. Saliva testing is an accurate tool used to measure testosterone.
42.h su域∝ts were representative oftypical olderコdes。
3.Androstenedione is a completely safe dietaFy supplement.
4.Altmtions h testosteЮne levels that may be seen are due only to
androstenedione supplernentation.
5。A ceiling erect for testosterone conversion is operating,which necessitates this
study。
Delimitatiolls ofthe Studv
TЪe delinlitations ofthis investigation are as fbnows:
1.01der males were thC SuttectS。
2.Only the erects ofl■timate Nutrition Androstenedione were mvesugated in a
single 200 mg dose.
3.C)nly saliva testing was used to lneasure testosterone levels.
4.Only bikes,treadmills,and Юwers were used in a speciic exercise plan.
5.Only RPE was used to measllre the eibrtlevel ofexercise workloads.
6.Only anger,宙gor,and fatigue were measured to assess mood.
Limitations ofthe Studv
Lc lirnitatiolls ofthis stndy are as follows:
1.■le results may only apply to older nlales with low testoSteЮne levels.
2.The results may only apply to tt effects ofUltimate Nutrition
Androstenedione supplementation in the specifled dose.
3.Results nlay only apply when■le tool ofmcasurement used is Saliva testing.
4. Results for RPE IIlay only apply when a similar exercise program is
employed.
55. Aspects of mood other than anger, vigor, and fatigue may not be affected as
the results described by this study.
Definition of Tenns
The following terms were operatisnally defined for the purpose of this
investigation:
1. Treatrrent goup- those subjects vfuo received androstenedione.
2. Confol group 
-those subjects who received aplacebo.
3. Older males 
- 
men who are over the age of 55'
4. Supplernentation- an artificial substance added to the human body to gain
normal levels, or exceed normal limits to profit from the effect.
5. Over-the-counter 
- 
a medicine that can be purchasd at adnrg store without a
prescription, such as aspirin and cough synry.
6. Andropause 
- 
a male form of menopause, characteized by low testosterone
levels, inteltectual slowing, abdominal obesity, and muscle atrophy.
Chapter2
REVIEW OF LITERATURE
Menopause, the cessation of re,productive tife in fernales, is awell-known
condition that begins in a woman's early forties. Menopause typically builds slowly over
a period of l0 years known as the climacteric, during which the levels of female sex
hormones, such as estrogen and progesterone, decline by up to 7|%o,marking the end of
ovarian functioning (Johnson & Everitt, 1984). Menopause symptoms include: irregular
menstnral periods, hot flashes, night sweats, disffibed sleep patterns, vaginal dryness and
shrinkage of genital tissues, dry skin, more frequent urination or leakage of urine, more
frequent minor vaginal and urinary tract infections, fatigue, loss of sexual desire, anxiety,
depression, tearfirlness, irritability, sleeplessness,lack of concentration' and memory
trouble (University of Michigan Health System). These symptoms are often reduced by
honnone replacement the.upy GRT). Recent research suggests that long-term HRT is
contraindicate4 but short-term use is still seen favorably @iscup, 2003; Chew & Ng,
2002; Shah & Alexander, 2003).
Men, like women, also experience a decrease in sex hormone production as they
age. The process is more gadual and is called andropause, which does not have a
noticeable start, but its symptoms usually become noticeable around 50 years of age.
These symptoms include: wealotess, fatigUe, reduced muscle and bone mass, impaired
hematopoiesis, decrease in spermatozoa, sexual dysfunction, depression, anxiety,
initability, insomnia, memory impairmen! and reduced cognitive frrnction 6un4 Bever-
Stille, &Perry,1999). Similar to menopause, treatment for andropause is androgen
replacement the.apy (ART). The most coflImon type of ART is testosterone
supplementation in the form of pitls, patches, or injections (Flieger, 1995)'
Some over-the-counter products are purported to be ART substitutes, such as
androstenedione, an androgen produced within the body, which when taken as a
supplement theoretically boosts testosterone levels. If testosterone levels in older males
7are increase4 than their psychological well-being, bone density, and lean body mass
should improve (Sadoesky, lgg/). Such benefits would be appreciated, but the claimed
actions of androstenedione are largely untested. This literature review focuses on the
foltowing: (a) what is androstenedione, (b) the biochemical relationship among
androstenedione, testosterone, and estrogen, (c) efrecS of testosterone and its relationship
to andropause, (d) effects of testosterone on exercise performance and mood, (e) research
on androstenedione, and (0 swnmary.
What is Androstenedione
Androstenedione is a Cle steroid produced primarily in the testes and secondarily
in the adrenal glands from testosterone or dehydroepiandrosterone @HEA) as shown in
Figure I (Schneider, 1978). The biochemical relationship among the sex hormones will
be explored more fully subsequently. After production, androstenedione is converted
back into testosterone, converted into estrogen, or secreted into ttre circulatory system'
From the blood it enters other tissues where it directly or indirectly exerts its
physiological effects (King et al., lggg). The normal secretion rate for t
androstenedione-3,l7 is 5 mg.d I (Sawin, 1969). Secreted androstenedione represents
about 8% of the circulating androgens in the body; relative to testosterone and 5cr-
dihydrotestosterone androstenedione is mildly androgenic (Johnson & Everitt, 1984)-
The most critical aspect of androstenedione for this study, however, is its potential for
conversion into either testosterone or estrogen-
Approximately 95o/oof the testosterone that is synthesized in the male body is
manufactured in the testes, primarily in the leydig cells and secondarily in the sertoli cells
(Jones, lggT). The other 5olo of testosterone is produced in the adrenal glands.
Irrespective of where it is made, most testosterone is manufactured from acetate and
8DHE4.
Fieure I . Pathways of Androstenedione
H●～
cholesterol, a pnocess influenced by luteinizing honnone (LtD, a gonadotropin released
from the anterior pituitary gland. LHatalyzes the combination of acetate and
cholesterol into pregnenolone, the precursor of all sex hormones, including testosterone,
progesterone, and estnogen In males, the enz5rme l7o hydroxylase converts the
pregnenolone into l7a-hydroxypregnenolone, which is then converted into DHEA by 17,
20 desmolase. DIIEA has several fates; it is either converted into androstenediol by the
enzyme l7a-hydroxysteroid dehydrogenase or androstenedione by the enzyme 3p-
hydrorysteroid dehydrogeoase. Androstenediol, in turn, is converted into testosterone by
the enzyme 3p-hydroxysteroid dehydrogenase (Johnson & Everitt, 1984). In contrast
androstenedione takes two pafhways with the predominant one being conversion to
testosterone by the en7.,qe l7o-hydroxysteroid dehydroganase. Less commonly, the
leydig cells secrete androstenedione into the general circulation. Some ofthe secreted
androstenedione enters nearby sertoli cells, which convert it into either testosterone or
estrogen with the enzyme aromatase (Johnson & Everitt, 1984). Approximately 3 mg'd 
t
of androstenedione is converted into estrogen at a transfer rate of l.syo,yielding 125-150
pg.d lof estrogen (Longcope, Kato, & Horton, 1969). Indee4 androstenedione is the
precursor for20-30%oof estogen in the body (Horton & Tait, 1966). The biochemical
interrelationship among androstenedione, testostcrone, and estrogen in the testes is
illustrated in Figure 2.
After its production in the sertoli cells, leydig cells, or cells of the a&enat glan4
testosterone has two fates: it is converted into other products by these cells or secreted
into the general circulation. Once in the general circulatioru testosterone enters target
tissues, where it exerts physiological effects or is converted into other products, which
then exert physiological effects. lrrespective of location, testosterone is ultimately
converted into one of three products: androstenedione via l7a-hydroxysteroid
dehydrogenase, estrogen by aromatase, or 5ct dihydrotestosterone (DHT) by 5ct
10
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Figure 2. The Biochemical Interrelationship among Androstenedione, Testosterone, and
Estrogen in the Testes.
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reductase. DHT is the most prrvalent and potent of the male androgens (Johnson &
Everitt" 1984).
Testosterone is the primary sex homrone in males (The Testosterone Source,
1999). It is responsible for producing the male reproductive system and influencing the
development of the brairL kidney, liver, muscle tiszue, as well as other parts of the body.
Testosterone production begins in the testes around the eighth week of fetal development
(Flieger, 1995). The testosterone concentration increases slowly until birttr, when it
drops substantially to a minute level, which is maintained until puberty, whereupon
production dragatically increases. The large surge in testosterone in males at puberty
induces many changes within the body, zuch as: voice deepening, facial hair glowttl
genital enlargemen! increased libido, and bone and muscle maturation. The testosterone
concentration continues to rise until it peaks in the twenties. After peaking, testosterone
Ievels drop by abogt l%o eachyear until death (Saunders, Montague, Levine, & Guay,
1998). Table I shows that the testosterone levels typically decrease from 617 to 376
ng.dl-I, a3lYoreduction, in males between the ages of 25-85'
As mentioned in the introduction of this chapter, somewhere around the age of 50
men may experience andropause, which is clinically diagnosed when testosterone levels
fall below 300 ng.dl-t (Jones, 1997). Affecting four to five million Americans,
andropause is caused by a decreased testicular response to gonadotropins, resulting from
reduced vascularization of the testes as well as a lowered number and availability of
leydig cells within them (Timiras, Quay, Vemadakis, 1995). Collectively, these changes
decrease the amount of testosterone produced by the body, which causes unwanted side
effects, such as: aMominal obesity, intellectual slowing, elevated voice pitch, decreased
facial hair growth, osteoporosis, depressior; decreased muscle mass, and irritability'
while also reducing sexual functioning (FDA Consumer, 1996; Jones, 1997i' Smith,
12
Table l.
No. of
25‐34
35‐44
45-54
55-64
66‐74
75‐84
85‐100
45
22
23
43
47
48
21
617
610
606
562
524
471
376
170
212
213
195
197
169
134
12.3
10.3
9。1
8.3
6。9
6.0
5。4
2.8
1.2
2.2
2.1
2.3
2.3
2.3
Note. source of chart: http://www.weymouthelinic.co-uk/wellman/paper'hml
Mcan Plasma TaosterOne LⅣel  fOrth AvemRc Male bv Att fng・dl‐
1)
Age Total     StandardFree   Standard
Testosterone Deviation Testosterone Deviation
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lgg4). Changes in sexual function include slower erections, and a decrease in the size of
the scrotunq penis, and seminal vesicles (Jones, 1997).
Andropause is a form of hypogonadisnq a hormonal deficiency that is estimated
to afflict approximately 5 million American males GDA Consumer, 1996).
Hypogonadism rezults from a multitude of reasons, but the effects are the same as
andropause @agatell & Bremner, 1996). To combat either condition, many men use
some form of ART, which slows the drop in testosterone, frequently returning it to
normal levels, thereby abating or reversing the changes associated with hypogonadism or
andropause.
Androstenedione is one purported type of ART. Theoretically it elevates
testosterone levels and consequently prevents or delays the symptoms associated with
andropause. It may also protect the body against heart disease, strokg prostrate cancer,
and osteoporosis by maintaining a healthy range of testosterone within the body (Jones,
1997;Rudman et al., 1994). Since ART, including possibly androstenedione, increases
psychological mood states in addition to improving physical capacities, it may also
enhance ability to exercise, another well-known modality that attenuates the effects of
aging (Craig, Brown & Everhart, 1989; Hurel et al., 1999;Ianierdo et al., 2001;
Suominen & Ratrkila, l99l; Young & Ismail, 1979). If ART were effective, then men
may be more likely to initiate exercise, possibly sustaining it at a greater intensity for a
longer duratioq thereby improving the benefits derived from exercise (Suominen &
Rahkila, l99l). In addition, if the exercise was of a greater intensity and duratioq it may
further improve natural androgen levels, as exercise is a known stimulus for androgen
secretion (Craig, 1989; Hurel et al., 1999). Exercise and ART could very well act
synergistically to improve vitality in older men.
Ef[ects of Exercise Performanc€ on Testosterone and Mood
It has been shown that abnormally low levels of testosterone can decrease lean
body mass, muscular strengttq and exercise tolerance (Pe.ry, 1999). These changes can
t4
reduce exercise duration, intensity and possibly frequency. If testosterone is elevated in
such individuals, moo{ strengttl and qualrty of life significantly improve (Ferrando et
al.,2OOZ;Lund, Bever-Stille, & Perry, 1999). These benefits occur independent of
exercise (Wang et al., 2000). Exercise alone, however, can elevate testosterone levels
over time (tlurel, L999;[Iakkinerl 2W2).In older males, for instance, 18 months of
exercise elevated testosterone levels, suggesting that exercise can partially counteract the
normal decline in hormones seen with aging (tlurel et al., 1999). In contrast to chronic
exercise, acute bouts of exercise have relatively no effect on testosterone levels @orst,
Vincent, Lowenthal, & BraittL 2}D2;Craig, Browrq & Everhart, 1989;Kraemer et al.,
2003; Smilios, Pilianidis, Karamouzis, & Tokmakidis, 2}03;Tremblay, Copeland, & Van
Helder, 2OO4;Zhou, et al., 2000). Thus, if one only performs acute bouts of exercise,
some form of ART may be needed to return testosterone to normal levels.
Even though acute bouts of exercise do not immediately raise testosterone, they
can positively affect mood stdes regardless of the person's age and sexq as well as the
duration, mode, intensity of the exercise bout (Annesi,2002; Fox, 1999; Hansen, Stevens,
& Coast, 2OOl;Lane & Lovejoy, 2001;McGowan, Pierce, & Jordarq l99l; Pierce &
Pate,1994). Both chronic and acute exercise decrease fatigue, anger, confusio4 tension,
and depressiorq while they increase vigor and quality of life. Collectively, acute and
chronic exercise improves mood states, whereas only chronic exercise elevates
testosterone levels. Thus concluding that, exercise coupled with some form of ART could
potentially help restore testosterone levels quickly and efficiently while benefiting from
mood alterations immediately.
Research on Androstenedione
Androstenedione may be one type of ART, but the conversion of this supplement
into testosterone is not well studied. The supplement was first synthesized in 1935
@hilips, 1997). In 1936, Dr. Charles Kochakian discovered that it possessed both
anabolic and androgenic effects (ColgarL 2000). The effects of androstenedione
15
supplementation were first studied in humans rm1962. Mahesh & Greenblatt (1962)
looked at plasma testosterone levels before and after oral consumption of 100 mg of
androstenedione in two women Although testosterone levels rose considerably in these
subjects, the applicability of these results to males was limited.
The next study to take place compared the rate of conversion of oral and injected
radio labeled androstenedione to testosterone in both males and females ages 21-33 years
(Horton and Tait, 1966). It was found that approximately 5.9% of injected
androstenedione was converted into plasma testosterone in contast to 1.8%o of orally
consuned androstenedione. Forty percent of intravenous androstenedione was converted
into urinary testosterone and excreted. In contrast 897o of orally administered
androstenedione was converted to urinary testosterone and excreted indicating that little
testosterone enters general circulation after oral consumption.
ln amore recent study,20 college-aged men either consumed 100 mg of
androstenedione or a placebo every day for 8 wk while completing a resistance training
program (King et al., 1999). There was no difference in fitress between the experimental
and control goup in this study. In addition, and more importantly, testosterone levels did
not increase in the experimental goup, whereas the estogen concentration did. These
authors suggested their findings may illustrate a ceiling effect in young, healthy males for
the conversion of androstenedione into testosterone. Since the subjects in this study had
normal testosterone levels, perhaps the androstenedione supplement could not be
converted into testosterone. krstea4 the supplement may have been shunted into the less
commonly used estrogen pathway (Greenspan & Ba:rter, 1994).
Data from Matresh and Greenblatt(1962) support the notion of a ceiling effect.
Since their subjects were womeq with lower testosterone levels than men,
androstenedione supplementation had better potential for and was readily converted to
testosterone. In short, the putative testosterone ceiling had not been reached in these
subjects. Two additional studies support the ceiling hypothesis (Rasmussen, Volpi, Gore,
16
& Wolfe, 2000; Wallace, Linr, Cutler, & Bucci, 1999). In both studies, the subjects were
young males (28-5Zy) who had normal testosterone levels. Despite consuming 100-300
mg of androstenedione per day, there was no acute change in testosterone levels in this
subject oohort. Estrogen levels, however, did significantly increase. Researchers
concluded that since the subjects already had normal testosterone levels, the
androstenedione supplement was converted to estrogen.
Summary
Androstenedione, a natural pr@ursor to testosterone may help alleviate symptoms
of andropause. Current literature suggests that androstenedione may not elevate
testosterone levels in young men with normal testosterone levels. These data may show a
"ceiling effect." In short, androstenedione may not boost testosterone in males with
normal levels, because there is no deficiency in the hormone. Instead, it is converted to
estrogen and eliminated from the body. In older men, however, those with low
testosterone levels, androstenedione may elevate testosterone levels because the ceiling
had not been reached. Consequently, if androstenedione were to allow older males to
produce normal ranges of testosterone once again, the possibility of increasing mood
states along with exercise performance should coexist.
Chapter 3
METHODS
This chapter describes the zubjects used in this study and outlines the
methodology of data collection.
Subiects
Twenty-five males between the ages of 55 and 85 volunteered to participate in
this study. Their descriptive characteristics are reported in Appendix A. Subjects were
recruited from the Heart Health Institute in Newingtoq NH. Prior to participation,
subjects were screened for current or former injuries, such as orthopedic limitations, that
could interfere with completion of the study. All subjects were asked to complete a
physical activity readiness questionnaire (PAR-Q). They were ineligible to be tested if
their questionnaire answers could not satisft the requirement ttrat they were healthy
individuals. The only test question that was accepted with a "yes" answer was in regards
to a doctor prescribing a diuretic or water pill, all others had to be answered "no" or the
subject was excluded from the study.
Each subject was also screened for a history of prostrate canc€r and the use of
testosterone replacement therapy. Although nine out of twenty-five subject had previous
cardiac events, no subject had any cardiac events vithin the past five years. Nor had any
recently experienced any shortrress of breath or chest pain with activity. All subjects had
been exercising for at least three times a week fs1 a minimum of three months
consistently. Before the first test, subjects read and signed an inforrred consent form that
had been approved by the Human Subjects Committee at Ithaca College (Appendix B).
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All were given a full explanation of the study along with the benefits, risks of
participation, and participation requirements.
Method of Data Collection
Brief Overview
Each subject reported to the Heaft Health Institute, Newingtoq NH on two
occasions. The first visit consisted of a submaximal bike test and a submaximal shength
test. Each subject retumed for a second testing day during which he received the
experimental interventioq provided three saliva samples, completed three POMS-short
fonns, and perforned the prescribed exercise program.
Submaximal Testing Day
Upon arrirring at the Heart Health lnstitute, Newington, NH subjects were
weighed on apre-calibrated scale (Detecto, Webb City, MO). Target heart rate rtulge was
calculated using the Karvonen method as follows: tQ20 - age - Resting Heart Rate) x
70o/ol+ Resting Heart Rate (American College of Sports Medicine, Guidelines for
Exercise Testing and Prescription,200l). Borg's RPE scale was then explained as a
subjective table that allows subjects to rate their perceived exertion (Appendix C). Next
the subject was fitted to his correct seat height on the cycle ergometer (True Fitness
Technology, [nc. model 750& O'Falloru MO) with legs at a full extension, leaving a soft
bend in the knee. Once fitted, a standard YMCA protocol (American College of Sports
Medicine, Guidelines for Exercise Testing and PrescriptiorU 2001) was used to assess
submaximal fitness. This test uses two to four, 3 min stages of continuous exercise.
Workload was increased each stage by 10 W to 30 W, as determined from the heart rate
(HR) response. The test was terminated when the subject attained approximately 70o/o of
l9
his age-predicted maximum HR HR and RPE were taken towards the end of the second
minute and again at the end of each stage to assess intensity and to determine if a steady
state IIR was obtained.
Fifteen minutes following the submaximal bike tes! maximum chest and leg
stength were assessed with l0 repetition maximum tests conducted on the Nautilus Chest
Press and Leg Extension machines (Independence, VA). The initial load was set at 100%
of the load normally lifted by the subject during their exercise regrmen. If l0 repetitions
were completed, then another set of l0 repetitions wene completed at higher workload (10
to 20 lbs greater depending on the ease of completion) and so on until the subject could
not complete 10 repetitions. There was 5 min of rest between trials and no subject
attempted more then three tials in a day. If the maximum was not found in three fiials,
the subject was retested 48 hours later. If the subject could not complete ten repetitions
at the initial [oad, then he completed additional trials every 5 min at progressively lighter
loads until the l0 repetition morimum was measured.
Intervention DaY
A single blind research design was used and subjects were randomly placed into
either a treafinent Soup or a contol group. No significant differences were seen between
groups prior to testing. Submaximal YMCA testing data were used to predict ma:rimum
MET levels for each subject. Individual exercise prescriptions were written for each
subject. Workload was set at approximately 70%o of his predicted ma:rimum capability of
the chest press,leg extension, and cardiovascular equipment. Metabolic equations
(American College Of Sports Medicine, Guidelines for Exercise Testing and Prescription,
2001) used to determine workload for the cardiovascular equipment are:
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Treadmill: METS : [(m / min x 0.1) + 3.511 3-5
Bike: METS: [(Watts x 6.1 x 2.0/ Weight in kg) + 3.5]/3.5
Rower: METS = [(Watts x 6.1 x 3.0/ Weight in kg) + 3.5]/ 3.5
Upon arival to the Heart Health lnstitute, Newington, NH, each subject rinsed his
mouth with water and then provided a small quantity of saliva, about 0.50 ml, which was
used to measure baseline testosterone levels (Bricaire et al., l99l; Chen, Bookstein, &
Meldrurn, l99l; Heinonen, 19921' Yen, l99l). Additional saliva samples were taken at
minutes 60 and 120 during the testing protocol. Each sample was transfened into a small,
pre-labeled tube that was sealed and placed in dry-ice until all sarnples were collected for
the testing session. Within three hours of initial data collectiorU the salvia sarnples were
stored in a -80 oC freezer. After completion of all testing, the samples were packed on
dry ice and shipped by UPS overnight to Ithaca College, where they were analy?rdusing
a Steroid Hormone ELISA Assays kit (Immuno Biological Laboratoreis, Hamburg,
Germany). Detailed procedures are shown in Appendix D.
After the initial saliva sampling, the treatrnent group consumed 200 mg of
Ultimate Nutrition Androstenedione (Farmington, CT), where as the control group
ingested a flour placebo. Next they completed a POMS-short forrr (see Appendix E)
before exercise started. Additional POMS forms were completed immediately after the
workout was finished and at 180 min after treatment. After the first POMS was
completed, subjects were given their individual workout card. The card outlined the
exercise regimen, which consisted of 20 min walking on the treadmill (True Fitness
Technology, Inc. model 7500,O'Fallon, MO), 15 min of cycle ergometery (True Fitness
Technology, Inc. model750R, O'Fallon, MO), l0 min of rowing (Concept II,
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Farmington" CT), and one set of 12 repetitions for the leg extension and chest press,
respectively. RPE was recorded at the end of the work bout for each piece of equipment.
Average RPE was then assessed for each individual on all four workout modes. All RPE
scores were then combined and averaged as a whole for each goup.
Statistics
A2 x 3 (group x time) analysis of variance (ANOVA) with repeated measunes on
the second factor was used 1s sxamine differences in salivary testosterone levels betrveen
groups over time. A2x3 (group x time) analysis of variance (ANOVA) with repeated.
measures on the second factor was also used to observe variation in mood states between
groups over time. The dependent variable was mood state (A- Anger-Hostilty, V- Vigor-
Activity, F- Fatigue-Inertia). A t-test was used to assess the differences in RPE between
groups using a single composite score for all exercises performed. A t-test was also used
to determine any initial difference in predicted VOz max levels between the groups. A
significance level was at p < 0.05 for all tests. The statistical analyses were run using the
SPSS/PC 10.0 program for an IBM compatible computer. A detailed description of
analyses is presented in the next chapter.
RESI.]LTS
In this chapter the results and statistical analyses of data are presented. Sections in
this chapter include the fotlowing: (a) subject characteristics O) testosterone levels (c)
profile of mood states and (d) rating of perceived exertion.
Subject Characteristics
The mean + SE for age, weight, and 70 % of VOzmax for the control group were
66.6 + 8.2. y, 92.1 + 13.9 kg, and 19.95 + 1.4 d-r'kg''-ir t, respectively. The
corresponding values for the treafinent group were 65.3 + 8.1 y, 89.9 + 16.5 kg, and
19.25 + 0.9 d-1.kg-l.min-l , respectively. There were no significant differences in these
variables between the groups. Details for subject characteristics and all raw data can be
seen in Appendix A.
Testosterone Levels
Means and standard deviations for testosterone levels are reported in Table 2. No
significant interaction was found between Group and Time in levels of testosterone. A
2x3 ANOVA revealed no significant main effect for Group, F(l,69) :3.480, p:0.066,
indicating there was no significant difference in the level of testosterone between the
control group and the treament Soup (see Appendix F, Table F-l). There was no
significantmaineffectforTime,F(1,69):1.449,p:}-24},indicatingtherewasno
significant difference in testosterone levels over the three time points (Figure 3).
Proflle ofMood States
Anger
No signincantinteracdon was fomd between Group and Time for anger
(Appendix F,F-2)。A2x3ANOVA revealed llo signiicant main effect for GЮ
up,11,69)
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Table 2
Mean+SD for Sdected Variables bv Group and Time
Variable
Contro1 0ouD
M  塑
Trmment Group
M  SD
Te飩o飩eЮne Levels cng/dl)
Time l
Time 2
Time 3
POMS Score―Ang r
Time l
Time 2
Time 3
POMS Score―Vigor
Time l
Time 2
Tillle 3
POMSS∞re―Fatigue
Time l
Time 2
Time 3
02.00    0.95
03.54ホ   2.26ホ
01.08*   1.75ネ
63.00   0.11
59.00   0.22
67.00   0.13
01.64    1.07
00.64*   1.28*
00.29*   2.04*
10.71    2.94
10.21    3.09
10.79    4.56
01.79    1.83
03.86*   2.96*
01.14*   1.70ホ
63.00
72.00
76.00
00.69
00.08ホ
00.00ホ
09.15
09,77
08.38
0.17
0.23
0.21
0.00
0.28*
1.29*
5.33
4.99
5.01
Note. Time 1 :0 min or pre-treatment, Time2:60 min post-treatment, Time 3: l2O
min post-treatment. * : significant dif[erence from Time 1.
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Mean and+SD for Testosterone Over Time
Figure 3.Mean and tt SD fortestosterone acЮss time.Tr ament=Treament Group色=
13);ContЮl=ContЮl(bЭup色=12).Time l=O min or pre‐treament,Time 2=60111m
post‐reatnent,Time 3=120 1nin post―treatnent.
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: l.75O,p:0.19q indicating there was no significant difference in anger between
treatment and control (Appendix F, Table F-2). There was a significant main effect for
Time, F(1,69) = 4.017, p:0.022, indicating there was a significant difference in anger
across time for both groups (Figure 4). The Tukey HSD test revealed that anger levels
decreased significantly from pretreatment to 60 min post-treatment and from pre-
treatment to 180 min post-treatment. Means and standard deviations for anger are
reported in Table 2.
Vigor
No significant interaction was found between Group and Time in vigor (Appendix
F, Table F-3). A 2x3 ANOVA revealed no significant main ef;Fect for Group, F(I,69):
1.396, p: 0.241, indicating there was no significant difference in vigor between the
treatment and control groups (Appendix F, Table F-3). There was no significant main
effect for Time, F(l,69) = 0.085, p = 0.919, indicating there was no significant change in
vigor over time (Figure 5). Means and standard deviations for vigor are reported in Table
)
Fatizue
No significant interaction was found between Group and Time (Appendix F,
Table F-4). A 2x3 AIIOVA revealed no significant main effect for Group, F(1,69):
0.106, p: 0.749, indicating there was no significant difference in fatigue between the
treatment and control groups (Appendix F, Table F-4). There was a significant main
effect for Time, F(1,69) = I1.196, p : 0.000, indicating there was a significant change in
fatigue across time @igure 6) in both groups. The Tukey HSD test revealed that fatigue
levels significantly increased from pre-treatment to 60 min post-treatment, and
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Mean and+SD for Anger Score Across Time
Figure 4. Mean and + SD for anger score across time. Treatnent: Treafinent Group @:
l3); Control: Control Group @: l2). Time 1 :0 min or pre-treatrnent, Time 2 :60 min
post-treatment, Time 3 : 180 min post-treatnent. * : significant difference from Time l.
?
?』
?
?
???【?
』
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Mean and±SD for Vigor Score Across Time
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Figure 5. Mean and + SD for vigor score across time. Treafrnent: Treatment Group (n:
l3); Conhol : Control Group (q: l2). Time I : 0 min or pre-treatnent, Time 2 : 60 min
post-treatmen! Time 3 : 180 min post-treatuent.
?
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Mean and+SD for Fatigue Score Across Tinhe
旦塾理菫」■Mean and tt SD for fatigue score acЮss time.T ament=Treament Group色
=13);Contr01=ContЮl Group色=12).Time l=O min or pre‐trealment Time 2=60
min post‐treatnent Time 3=180 min post¨treament.*=signincant direrence hm
TilElle l.
? 〓??
??〕【?』
囲
ChaPter 5
DISCUSSION
Androstenedione is produced naturally within the human body, and serves a
precursorto testosterone (Johnson & Everitt, 1984). Bas€d on this biology, zupplement
manufactures claim that oral consumption of androstenedione elevates serum testosterone
levels. Numerous studies have tested but not confirmed these claims (Greenspan &
Baxter, 1994;Horton &Tait,l966;King et al., 1999; Rasmusserq Volpi, Gore, & Wolfe,
2000; Wallace, Lirn, Cutler, & Bucci, 1999). Since the subjects in these studies were
between the ages of 18 and 55, and had testosterone levels within the normal range of
376to 617 ng.dl-t (http://www.weymouthelinic.co.uk/wellman/paper.html.), it is possible
that the ingested supplement could not be converted to testosterone, because a
testosterone ceiling may have been reached. This may explain the increase in estrogen
levels found in the subjects ofthe aforementioned studies. If consumed androstenedione
cannot be converted to testosterone, it may be eliminated via the less commonly used
estrogen pathway Qlorton & Tait, 1966). To determine ifthe conversion of orally
consumed androstenedione to testosterone is limited by initial testosterone level, this
study examined the effects of the zupplement in older males, who typically have lower
testosterone levels than the 18 to 55 y old subjects in the aforementioned studies.
Testosterone levels in my subjects ranged ftom22.6to 85.4 ng'dl-r, which is below
normal and less than the range of 376 to 617 ng'dl'r reported in the aforementioned
studies. Despite the low initial levels of testosterone and the consumption of the
recommend dos4ge of androstenedione, the product did not alter serum testosterone
levels. Therefore, it seems unlikely a ceiling effect limits the conversion of orally
consumed androstenedione to testosterone. Indeeq the collective data from all studies
that have examined androstenedione suggest that orally consumed androstenedione is not
converted to testosterone.
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The secondary purpose of this study was to determine if androstenedione
supplementation affected aspects of exercise performance reported by RPE and POMS
betrveen the groups. It was thought that the zupplement could conceivably improve
exercise performance and the perception of exercise performance if it elevated
testosterone levels (Craig, Brown, & Everbart, 1989; Hurel et al., L999;Izuierdo et al.,
2001; Suominen & Rahkila, l99l; Young & Ismail, 1979). Although we did not measure
changes in exe,rcise performance by tracking HR or weight lifte4 RPE is a valid measune
of exercise intensrty (Foster, 2001;Goss et a1.,2003; Herman, Nagelkirlq Pivarnih &
Womach 2003;Kang, Hoffinan, Walker, Chaloupka, & Utter,2003). There were no
dif;lerences in RPE between the groups, showing that the supplement did not alter
exercise intensity or perception of exercise effort. The RPE data are supported by the
POMS data which included analyses of anger, vigor, and fatigue. There was no
difference in these variables between the groups. Androstenedione, therefore, did not
alter exercise performance or the perception of exercise performance. A likely
explanation for these findings is that the supplement did not alter testosterone levels as
previously described.
We did note that there were significant differences across time in anger and
fatigue in both groups. Anger decreased significantly during and after exercise, whereas
fatigue increased during exercise and decreased after relative to baseline. These data
concur with other studies (Annesi, 2002;Fox, 1999; Hansen" Stevens, & Coast, 2001;
Lane & Lovejoy, 2001). The drop in fatigue and anger, relative to baseline, after exercise
suggests ttrat ttre short bout of exercise improved mood, which is also consistent with the
literature (Bartholomew & Miller,2002; Dilorenzo et al., 1999 Rehor, Dunnagan,
Stewar! & Cooley, 2001). Therefore, it can be claimed that exercise is beneficial in
altering mood state in a positive manner with only a short bout of exercise.
We also noted that short-term exercise did not independently increase testosterone
levels. This finding agrees with other studies in which the effect of short-term exercise
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on t€stosterone in middle-aged and older me,o and women was examined (Borst, Vincent,
Lowenthal, & Braitb 20O2; Smilios, Pilimidis,IGramouzis, & Tokmakidis' 2003; hou
Lin, JirU 1g1e,hao,& Wang 2000). Although single bouts of activity do not significantly
alter testostenone levels, several months of regular exercise does increase the resting
concentration ofthis hormone Gtal*inen et al., Zffi2;Izquierdo et a1.,2001)'
Summar.v
Single dose androstenedione sup,plemelrtation in older males did not affect
testosterone levels even though the subject cohort had below normal initial testost€rone
levels. These results suggest rhat there is no ceiling effect limiting the conversion of
orally consumed androstenedione to testostercne. These data when combined with the
data from the other studies on the effects of adrostenedione supple,rnentation, suggest
that orally consumed androstenedione is not converted to testosterone. In additiorL
androstenedione zupplementation did not alt€r RPE or POMS during an acute bout of
exercise- Collectively, thesc data show that older malss will not benefit from
androstenedione supplementation.
Chapter 6
ST]MMARY, CONCLUSIONS, A}.ID RECOMMENDATIONS
Summary
This study examined the effects of androstenedione and its purported effect as a
natural precursor to testosterone. Secondarily, this study focused on the effects of
androstenedione on exercise responses. Twenty five older male subjects volunteered to
participate in this study. Each subject reported to the testing site on two occasions. The
first visit consisted of a subma:rimal bike test and a submaximal strength test. Each
subject returned for a second testing day during which he received the experimental
interventiorq provided three saliva samples, completed three POMS-short forms, and
completed an exercise program.
No significant differen@s were seen in testosterone levelsover time in either the
control or treatment group. No significant interaction (p < 0.05) was found between
group and time in regards to anger, uigoq or fatigue. There were however, significant
changes in anger and fatigue over time in both Soups, indicating this was due to exercise
and not androstenedione treatment. The Tukey HSD test revealed that anger significantly
decreased at both 60 and 180 min post-treatment, whereas fatigue increased significantly
from pre-treatment to 60 min post-treatment, and decreased significantly from pre-
tr@tment to 180 min post-treatment (Table 2).
Therefore, it appears that a single dose of androstenedione supplementation is not
effective in increasing testosterone levels or enhancing mood state in older men. No
ceiling effect was found to occur, suggesting that older males would not benefit
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from androstenedione supplementation. It can also be speculated that short-term exercise
does not alter testosterone independently in older men-
Conclusions
The results of this study yielded the following conclusions:
1. Androstenedione does not significanfly alter testosterone levels in older men.
2. Androstenedione does not significanfly alter mood state or exercise
perception.
3. Single bouts of exercise do not signfficantly affect testosterone levels.
4. Single bouts of exercise can decrease anger, affect fatigue and generally
improve mood in older men.
Recommendations
The following recommendations for further study were made after the completion
of this investigation:
l. Different types and different brands of androstenedione should be tested.
2. A future study in older men should measure circulating and urinary
androstenedione levels to determine the route of supplemental androstenedione removal.
3. A similar study using a more conventional ART supplement (e.g. testosterone)
shoutd be completed to determine if ART can impact exercise perfonnance.
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APPEND:XA
RAW DATA
age                70%Vo2
Subi。(yrs)hICm)Wくkg)(mllkgrmin)grOup lme
1   85  182.88  70.91    18.55     T    l
2   70  185.42  88.18    18.55     C    l
3   55  180.34  70.00    28.70     T    l
4   66  177.80  89.09    17.50     T    l
5   73  177.80 102.27   17.50     C    l
6  70 190.50 96.36   14.00   T   l
7   60  175.26  99.32    22.05     T    l
8   61  172.72  88.64    18.55     C    l
9   73  180.34  80.45    17.50     丁    1
10  76  175.26  90.45    24.50     C    l
l1   57  177.80 114.09   12.25     T    l
12  66  170.18  76.36    23.10     C    l
13   62  167.64 120.91   17.15     T    l
14   55  172.72 101.36   22.40     C    l
15   62  187.96 106.36   17.85     C    l
16   58  182.88 120.45   19.25     C    l
17   68  180.34  91.82    18.20     T    l
18  65  180.34  75.00    19.95     C    l
19  61  177.80  83.18    27.30     丁  1
20   63  177.80  92.73    19.60     T    l
21   64  180.34 69.55    18.90     T    l
22   85  175.26  73.64    13.30     C    l
23   68  167.64  86.36    18.90     C    l
24   68  172.72  84.55    23.80     C    l
25   59  172.72 103.18   22.40     C    l
1   85  182.88  70.91    18.55     T    2
2   70  185.42  88.18    18.55     C    2
3   55  180.34  70.00    28.70     T    2
4   66  177.80  89.09    17.50     T    2
5   73  177.80 102.27   17.50     C    2
6   70  190.50  96.36    14.00     T    2
7   60  175.26  99.32    22.05     T    2
8   61  172.72  88.64    18.55     C    2
9   73  180.34  80.45    17.50     T    2
10   76  175.26  90.45    24.50     C    2
11   57  177.80 114.09   12.25     T    2
12   66  170.18  76.36    23.10     C    2
13   62  167.64 120.91   17.15     T    2
14   55  172.72 101.36   22.40     C    2
15   62  187.96 106.36   17.85     C    2
16   58  182.88 120.45   19.25     C    2
17   68  180.34  91.82    18.20     T    2
18   65  180.34  75.00    19.95     C    2
19  61  177.80  83.18    27.30     T    2
20  63  177.80  92.73    19.60     T    2
21   64  180.34  69.55    18.90     丁   2
btosterone POMS POMS POMS
(ngrdり   Anger Vlgor Fatigue RPE
56.90 0 5
68.40 0  15
06.00 0  13
68.00 0  10
64.00 0 11
69.9     0  10
60. 0 0  5
85.40 0  13
67.30
70.80
70.30
0 17
0  2
0        11
0  雨ヽ
O N′A
O   N′A
3  NIA
4 NノA
O   N′A
3  NノA
O  NrA
O    N′A
O  N′A
2  N′A
2  N′A
l   N/A
2  N′A
2  N′A
6   NノA
5    N′A
4   NノA
O    N′A
2   N′A
3  N′A
O   N′A
O NノA
2    N′A
4   NノA
l    13.25
1    12.75
0    12.5
6     12.5
5  12
9     11
6  12.75
4  12.75
0    11.5
2   12
6 13.5
4 13.25
8 12.75
6    12
4    12
5 11.5
6 13.25
8  1175
2    12
4 11.75
2    12.25
69.00 0 9
70.20 4 13
65.20 1 3
60.40
74.40
2  6
4  1
73. 0  1 11
73.70 0 12
64.30 0    10
39.80 6  9
45.80      4    12
22.60      0   0
35.30      0     10
69.40      2    12
64 6   0 10
28.20 0  0
52.40 0  9
44.50 0  13
0 10
1 11
0  4
0  6
59.10
9.40
24.1
53.1
73.30 0 4
56.10 0 15
78.60      0    9
84.10     0 13
77.80      0     4
85.00  0 6
79.00  0 8
102.30 0 4
83.30  0     14
87.30      0     0
86.00      0    0
62.00  0   11
44.20
77.20
9
3  1
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RAW DATA
Sソ・盟胤毬警P(Ⅷ°gTp T
23  68  167.64  86.36    18.90    C    2
24  68  172.72  84.55    23.80    C    2
25  59  172.72 103.18   22.40    C    2
1   85  182.88  70.91    18.55    T    3
2   70  185.42  88.18    18.55    C    3
3   55  180.34 70.00    28.70    T    3
4   66  177.80 89.09    17.50    T    3
5   73  177.80 102.27   17.50     C    3
6   70  190.50  96.36    14.00    T    3
7   60  175.26 99.32    22.05    T    3
8   61  172.72  88.64    18.55    C    3
9   73  180.34  80.45    17.50    T    3
lo   76  175.26  90.45    24.50    C    3
11   57  177.80 114.09   12.25    T    3
12  66  170.18 76.36   23.10    C    3
13   62  167.64 120.91   17.15    T    3
14   55  172.72 101.36   22.40    C    3
15  62  187.96 106.36   17.85    C    3
16   58  182.88 120.45   19.25     C    3
17  68  180.34  91.82    18.20    T    3
18  65  180.34  75.00    19.95    C    3
19  61  177.80  83.18    27.30    T    3
20  63  177.80 92.73    19.60    T    3
21   64  180.34 69.55    18.90    T    3
22   85  175.26 73.64    13.30    C    3
23  68  167.64  86.36    18.90    C    3
24  68  172.72  84.55    23.80    C    3
25   59  172.72 103.18   22.40     C    3
testosterone POMS POMS POMS
(ngrd:)   Anger Vlgor Fattue RPE
54.30
77.60
72.80
86.50
63.70
69.40
52.40
o     o     0   11.75
0    12     1    11.25
o     12     2    11.5
o    10    4    10
o   lo   l   NノA
o   17    0   NノA
o    lo    O   NJA
68.60 0   12    0   NノA
12.90 0  10   2   N′A
42.10 4   7    6   N′A
83.00  0    8    2   NノA
86.30 0   15    0   N′A
68.90 0   15    0   N′A
32.40  0   6    2   NノA
78.40 0  10    2    N/A
76.30     0  3    2    N′A
75. 0     0 5     0    NノA
80.00     0 5     2    N′A
89.70 0 1    2   N′A
79 80  0  15   1   NノA
84.30 0 11    4   N′A
85. 0     0 10    0    NノA
64.40 0  15    0    NJA
50.90
66.20
66.70
93.70
81.20
o   9 1    N′A
0 13   0   N′A
o    o    O   NノA
o lo  O   N′A
o 9   1    N′A
88.60  0  8     2    NノA
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Info.11led Corlsent Fo■111
The Erects Of Androgen Supplementation on Testosterone
Levels in C)lder Males
1. Purpose of the study:
This study is being conducted to assess the change in testosterone levels during the
consumption of androstenedione.
2. Benefits of the study:
This study may identiff a method that will raise testosterone levels. This could help
overcome symptoms such as low energy levels, muscular weakness, irritability, and
lack of sexual desire. These findings could be extremely important to the millions of
American's that have hypogonadism (a lack of testosterone). All testing associated
with this study will be done free of charge and the results will be provided to you if
you so request.
3. Your Participation Requires:
First you will attend a brief meeting where you will be given a full explanation of the
details of the study. Any questions you might have will be answered at this time.
Next, each subject will provide a saliva sample used to measure testosterone levels.
This noninvasive, simple procedure involves the participant spiffing into a cup. Once
all saliva samples are obtained, the subjects will each consume a pill. Half will
receive 200mg of androstenedione and half, a placebo. Androstenedione is sold over-
the-counter as a dietary supplement. No acute, adverse effects have been documented,
and its effects are believed to be acute. You will then continue with your regular
workout protocol. Saliva samples will be taken 20 min. post treatment, 45 min. post
treatment, and 7 5 min. post treatment. Upon completion of your workout, you will be
asked to complete a short questionnaire describing your workout performance. Total
participation time for each subject in this project is 2 hours.
4. Risks of Participation:
There are always slight risks involved with a testosterone study, but they are minimal.
Since there is limited evidence of the product used, there has been no documentation
showing any acute, adverse effects. The treatment has been hypothesized to increase
testosterone levels within the body. If this is true, some effects of increased
testosterone levels could be seen if taken for an extended period of time. These
effects could include such effects as an increase of acne, rash, flushing, sweating,
dizziness, headache, fatigue, tremors, paresthesias, anxiety, insomni4 carpal tunnel
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syndrome, clamps, spasms' inq€ased B/P, nausea' vomiting, constipation, weight gin'
clnj,nctival eaema nara congestion, abnormal GTf, hair loss (male pattern
UutOo.s), insomnia, an decrease in IIDL Cholesterol, and apossible increase in the
risk of developing prostrate can@r. These effects are acute and will diminish within a
few hours of ceasing ftatment. However the effects occur only ufuen testosterone
levels are odremefnigt for an extended amount of time. Since our subjects have
diminishing testosterone levels and will not be consuming androstenedione for any
length of time, it is higfiy unlikely for any srch effects to occur' Also
andiostenedione does-noihave any docunentation showing adverse effects. It is not
recommended that zubjects continue to use these aides after the experiment has
c€as€d.
For more information:
If you would like more information about this sndy at anytime prior to, during-, or
foilowing the data collectioru you may contact either Samantha I . McCarlhy 207 I
6984477 or Tom Swensen 274-3114, or email at smccartl@hofinail'com
Withdrawal from the studY:
Participation in this study is voluntary and you may withdraw at any time if you so
choose.
ConfidentialitY:
Infonnation gathered during this study will be maintained in complete confidence.
Only S. l. trrtcCarthy and T. Swensen will have access to this infonnation. All
,"porti"g of this information to outside parties will be done in group form. You and
y* r.i" will never be associated with this information in any funre disclosures.
I have read and understood the above document I agree to participate in this study
and realize that I can withdraw at anytime. I also understand'that I can and should
address questions related to this study at any time to the researchers involved. I also
veriry that I am at least l8 years ofage.
Name of Subject (please prinQ
Signature of Subject Date
6。
7.
t.
APPENDIX C
BORG'S RA‐OF PERCEIVED EXERTION
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
V"ry, Very Light
Vtt H山
Fairly Lie■t
Somewhat Hard
Very Hard
V".y, Very Hard
Hard
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APPENDX D
ELISA METHODOLOGY
Testosterone ELISA
Cat.-No. : RE 52151
Size : l2x8
Storage : l-8 oC
Enrymeirnmunoassay (miootiter sfiips) for the quantitative determination of
testosterone in human serum and plasma
Instructions for Use
1. Preparation of Reagents
. Wash Buffer: Dilute l:40 with distitled water (e.g. l0 ml concentate *
390 ml dist. water). Store at room temperature for up to 8 weeks.
2. Specimen Collection and Storage
. Samples: Serum, plasma Storage for up to24hat2'8 "C,longer storage
at -20 oC. Avoid repeated freszing and thawing'
3. Assay Procedures
. Storage of reagents at2-8 oC. Allow reagents to react room temperature.
a. Pipet 25 pl of Standards, controls and samples'
b. lncubate 5 minutes at room temperature (18-24 'C)'
c. Add 200 pl of Enzyrne Conjugate to each well'
d. Incubate 60 minutes at room temperatue.
e. Wash* each well3 x with 400 pl Wash Buffer.
f. Pipet** 200 ofTMB-Substrate Solution.
g. Incubate 15 minutes at room temperature.
h. Pipet** 100 pl of TMB-Stop Solution.
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i. Briefly mix contelrts, Iead the optical density at 450nm (reference wave
length600-650 nm) within 30 minutes after stopping'
*Wash procedure is essential for the assay results'
***Stop solution should be pipetted afterincubation in the same time intervals
as the substrate solution-
On a semi logarithmic graph paper the concentrations of the standards (x-axis,
G*ith.i")-are plorci"g"il"t th"ir ophcal densities (y-oris, tinear).Patient results ared;-dt*"tli tom tUe S"if, constnrcted form the standads. Samples witn .r*$9s above
O. nign""t'rt 
"arra 
no:r" to be diluted with zero standard. In the case, the additional
dilution factor has to be taken into accotmt'
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APPENDⅨ F
ANOVA SUMMARY TABLES
Table F…1
ANOVA Summary Table for TdOSterone
?
?dfSS MSSource
Crroup
Time
Group x Time
Error
0。155
0.096
0.052
2.279
1
2
2
69
0。115
0.048
0.026
0.033
3.480
1.449
0.785
0.066
0.242
0.460
Table F‐2
ANOVA Summary Table for Anger
Source dfSS
Group
Time
Group x Time
Error
2.355
10。812
0.466
92.859
1
2
2
69
2.355
5。406
0。233
1.346
1.750
4.017
0.173
0。190
0.022ホ
0。841
Note.*pく0.05
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Table F-3
ANOVA S―ry Table for Vigor
Group
Time
Group x Tine
Error
25。855
3.142
11。355
1277.9100
1
2
2
69
25。855
1.571
5.678
18.520
???
???
??
??
??????
?
0.241
0.919
0。737
Table F-4
ANOVA S―ary Table for Fatigue
MS
??
Group
Time
Group x Time
Error
0。455
96.514
3.501
297.404
1
2
2
69
0.455
48.257
1.750
4.310
0。106
11.196
0.406
0.746
0.000*
0。668
Note.ホp<0.05
Source dfSS
